Mirum Pharmaceuticals (MIRM) Q2 FY26 earnings call

Mirum Pharmaceuticals delivered a strong Q2 FY26, driven by robust commercial execution and increased full-year sales guidance. The company advanced its pipeline with key milestones, including Breakthrough Therapy Designation for volixibat in PSC and completed enrollment for the VANTAGE study in PBC. However, regulatory discussions for volixibat in PSC will delay its NDA submission, requiring further iterative engagement with the FDA.